CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)

https://www.carb-x.org

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating early stage antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is investing up to $500 million between 2016 and 2021 to support innovative antibiotics, vaccines, rapid diagnostics, and other life-saving products. CARB-X focuses exclusively on high-priority drug-resistant bacteria, especially Gram-negatives. The scope of CARB-X funding is restricted to projects that target drug-resistant bacteria highlighted on the Centers for Disease Control and Prevention (CDC)’s 2013 Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the World Health Organizaton (WHO) in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. CARB-X is led by Boston University. CARB-X funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services (HHS), the Wellcome Trust, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). CARB-X is headquartered at Boston University School of Law. *

	Start	2016-07-28 established jv
	Industry	antibiotic
	Industry 2	drug development
	Person	Outterson, Kevin (Boston Univ 201703 Prof of Law + CARB-X Executive Director)

	Region	Boston, MA
	Country	United States (USA)
	Street	765 Commonwealth Avenue Suite 1204
	City	02215 Boston
	Tel	+1-617-353-3097
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	480,000,000 (funding, overall (2019) 2019-03-14)

		* Document for »About Section«: Peptilogics. (2/25/20). "Press Release: Peptilogics Announces CARB-X Funding to Accelerate Development of First-in-Class Antibiotics to Address the Rising Global Threat of Drug-Resistant Bacteria".

		Record changed: 2023-12-18

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)